Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

NCT03283384 is registered in ClinicalTrials.gov with Borstkanker Onderzoek Groep as lead sponsor.

NCT NCT03283384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Lead sponsor
Borstkanker Onderzoek Groep
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 15, 2019
Completion date
August 31, 2027
Enrollment
100 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms